Respiratory Medicine
Volume 103, Issue 9 , Pages 1320-1328 , September 2009

Remote daily real-time monitoring in patients with COPD – A feasibility study using a novel device

Received 25 November 2008 ,Accepted 24 March 2009.

References 

  1. Jadwiga A, Wedzicha A, Wilkinson T. Impact of chronic obstructive pulmonary disease exacerbations on patients and payers. Proc Am Thorac Soc. 2006;3:218–221
  2. Spencer S, Calverley PMA, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004;23:698–702
  3. O'Reilly JF, Williams AE, Rice L. Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J Clin Pract. 2007;61:1112–1120
  4. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries JD, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418–1422
  5. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–852
  6. Anthonisen NR, Manfreda KJ, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbation of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196–204
  7. Donaldson GC, Wedzicha JA. COPD exacerbations. 1: Epidemiology. Thorax. 2006;61:164–168
  8. American Thoracic Society . Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152:S77–S120
  9. Celli BR, MacNee W, Agusti A, Anzueto A, Berg B, Buist AS, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position. Eur Respir J. 2004;23:932–946
  10. Rodriguez-Roison R. Towards a consensus definition for COPD exacerbation. Chest. 2000;117:398S–401S
  11. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J. 2003;21:46S–53S
  12. Seemungal TAR, Donaldson GC, Bhowmik A, Jefferies DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1608–1613
  13. Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169:1298–1303
  14. Wedzicha JA, Calverley PMA, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19–26
  15. Gadoury MA, Schwartzman K, Rouleau M, Maltais F, Julien M, Beaupré A, et al. Self-management reduces both short- and long-term hospitalisation in COPD. Eur Respir J. 2005;26:853–857
  16. Kida K, Katsura H, Yamada K, Motegi T, Mizuno S. Guided self-care using daily recording of peak expiratory flow and diary description for chronic airway obstruction in the elderly. Geriatr Gerontol Int. 2001;1:18–24
  17. Jones P, Higenbottam T. Quantifying of severity of exacerbations in chronic obstructive pulmonary disease. Adaptations to the definition to allow quantification. Proc Am Thorac Soc. 2007;4:597–601
  18. Sarfaraz S, Jarad NA. The use of mobile technologies in early detection of pulmonary exacerbation of CF, time to be precise [abstract]. J Cyst Fibros. 2005;4(Suppl. 1):PS61
  19. Medical research council questionnaire on respiratory symptoms; 1976.
  20. British Thoracic Society and the Association of Respiratory Technicians and Physiologists . Guidelines for the measurement of respiratory function. Respir Med. 1994;88:165–194
  21. Hajiro T, Nishimura K, Jones PW, Tsukino M, Ikeda A, Koyama H, et al. A novel, short, and simple questionnaire to measure health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159:1874–1878
  22. BTS/NICE . National clinical guideline on management of chronic obstructive pulmonary disease in adults and primary and secondary care. Thorax. 2004;59(Suppl. I):www.nice.nhs.uk
  23. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1618–1623
  24. Tashkin DP, Celli B, Senn S, Bukhart D, Kesten S, Menjoge S, et al. the UPLIFT Study Investigators A 4 year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–1554
  25. Wouters EF. Economic analysis of the confronting COPD survey: an over of results. Respir Med. 2003;97(Suppl. C):S3–S14
  26. Sridhar M, Taylor R, Dawson S, Roberts NJ, Partridge MR. A nurse led intermediate care package in patients who have been hospitalised with an acute exacerbation of chronic obstructive airway disease. Thorax. 2008;63:194–200
  27. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease; the ISOLDE trial. BMJ. 2000;320:1297–1303
  28. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789

PII: S0954-6111(09)00100-0

doi: 10.1016/j.rmed.2009.03.017

Respiratory Medicine
Volume 103, Issue 9 , Pages 1320-1328 , September 2009

Article Tools

* Image Usage & Resolution